Abstract:Computational systems biology employs computational algorithms and integrates diverse data sources, such as gene expression profiles, molecular interactions, and network modeling, to identify promising drug candidates through repurposing existing compounds in response to urgent healthcare needs. This study tackles the urgent need for rapid therapeutic development against emerging infectious diseases. We introduce a novel analytic expression for sensitivity analysis based on the Kronecker product and enhance model prediction performance using Graph Convolutional Networks (GCNs) with sensitivity-based graph reduction. Our algorithm refines prediction performance by leveraging sensitivity-based graph reduction. By integrating RNA-seq data, molecular interactions, and GCNs, we identify disease-related genes and pathways, construct heterogeneous graph models, and predict potential drugs. This approach involves novel analytical expressions that assess sensitivity to model loss, employing the Kronecker product approach. Subgraph analysis identifies nodes for removal, leading to a refined graph used for model retraining. This cost-effective pipeline focuses on computational methods for drug repurposing, targeting infectious diseases such as Zika virus and COVID-19 infection. Applied to these infections, our methodology integrates 659 proteins and 703 drugs for Zika virus, and 495 proteins and 468 drugs for COVID-19, along with their interactions derived from gene expression profiles. Top candidate drugs, such as Betamethasone phosphate and Bizelesin for Zika virus, and Chloroquine, Heparin Disaccharide, and Resveratrol for COVID-19, were validated through literature review or docking analysis. This scalable approach demonstrates promise in repurposing drugs for urgent healthcare challenges.

Computational repurposing of drugs for viral diseases and current and future pandemics

Computational drug repurposing for viral infectious diseases: a case study on monkeypox

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19

Recent computational drug repositioning strategies against SARS-CoV-2.

Drug repurposing prediction for COVID-19 using probabilistic networks and crowdsourced curation

An in silico drug repurposing pipeline to identify drugs with the potential to inhibit SARS-CoV-2 replication

Machine-Learning Driven Drug Repurposing for COVID-19

Computational Approaches to Designing Antiviral Drugs against COVID-19: A Comprehensive Review

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

Computational Drug Design Strategies for Fighting the COVID-19 Pandemic

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Repurposing Drugs for Infectious Diseases by Graph Convolutional Network with Sensitivity-Based Graph Reduction

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Drug Repurposing in the Chemotherapy of Infectious Diseases

Pandemic preparedness: On the efficacy of non‐pharmaceutical interventions in COVID‐19 and about approaches to predict future pandemic viruses

A molecular dynamics simulations analysis of repurposing drugs for COVID-19 using bioinformatics methods

Computational Drug Repositioning and Elucidation of Mechanism of Action of Compounds against SARS-CoV-2

Drug Repurposing: An Effective Tool in Modern Drug Discovery

Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies